AgPlus Electrochemical COVID-19 Diagnostic Assay

AgPlus 电化学 COVID-19 诊断分析

• 批准号: 69258
• 金额: $ 6.31万
• 依托单位: AGPLUS DIAGNOSTICS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=69258
• 关键词: AgPlus; Electrochemical; COVID; 19; Diagnostic

SARS-CoV-2 or COVID-19 is currently spreading throughout the world. Little is understood about the virus but we are learning fast and it is clear that we need to have good, accurate diagnosis to support quarantine and treatment.What is known is that the virus has a serial interval of 4 days and 1-3% of the population may be pre-symptomatic but still transmitting the virus. It takes 2-14 days to show symptoms after infection with the 97% of people developing symptoms within 11.5 days. This is a global challenge to halt the spread of the disease before our healthcare systems become overwhelmed.AgPlus' diagnostic assay for detecting specific immune responses to the COVID-19 virus will allow for a) confirmatory testing (rule in rule out) of those with symptoms, understanding that in some instances the symptoms may be due to bacterial infection b) monitoring treatment efficacy in those that have tested positive to ensure they are responding and when safe to release from isolation c) potential to be a companion diagnostic to support drug/ vaccine development d) test to confirm if patient has previously been infected with COVID-19\.

SARS-CoV-2或COVID-19目前正在全世界蔓延。我们对该病毒了解甚少，但我们正在快速学习，很明显，我们需要有良好的，准确的诊断，以支持隔离和治疗。我们所知道的是，该病毒有4天的连续间隔，1-3%的人口可能是症状前，但仍然传播病毒。感染后2-14天出现症状，97%的人在11.5天内出现症状。在我们的医疗系统不堪重负之前阻止疾病的传播是一个全球性的挑战。AgPlus用于检测对COVID-19病毒的特异性免疫反应的诊断检测将允许a）确认测试（rule in rule out）在有症状的人中，理解在某些情况下症状可能是由于细菌感染B）监测那些检测呈阳性的患者的治疗效果，以确保他们有反应，并在安全时解除隔离c）可能成为支持药物/疫苗开发的伴随诊断d）检测以确认患者以前是否感染过COVID-1，19\.